Radiation Oncology Department, Capio Fundación Jiménez Díaz University Hospital, Avenida Reyes Católicos No. 2, 28040 Madrid, Spain.
Cancer Treat Rev. 2013 Aug;39(5):421-9. doi: 10.1016/j.ctrv.2012.12.009. Epub 2013 Feb 1.
Merkel cell carcinoma (MCC) is a rare primary cutaneous carcinoma of the skin who has high aggressiveness, high risk of locoregional and distant spread, a mortality rate considerably higher than that of cutaneous melanoma and a poor survival. Its incidence has increased during the past twenty years. The studies published from 2008 to early 2012 have introduced interesting changes in the understanding of its epidemiology, pathogenesis and consequently in the diagnostic codes and the therapeutic approach. Early and detailed nodal diagnosis with posterior multidisciplinary decision is mandatory. Surgery and Radiotherapy play a fundamental role in the management of this tumor. Both are associated with improved locoregional control and disease free survival; but patients continue to have distant failure because, currently, there is no effective systemic treatment available. Consequently, there remain controversies about its appropriate management, and this review is an attempt to contribute to their clarification.
默克尔细胞癌（Merkel cell carcinoma，MCC）是一种罕见的皮肤原发性皮肤癌，具有高度侵袭性、局部和远处播散的高风险、死亡率明显高于皮肤黑色素瘤和预后不良。在过去的二十年中，其发病率有所增加。2008 年至 2012 年初发表的研究在其流行病学、发病机制方面引入了有趣的变化，进而影响了诊断编码和治疗方法。早期和详细的淋巴结诊断结合多学科的后续决策是必要的。手术和放疗在这种肿瘤的治疗中起着重要作用。两者都与局部区域控制和无病生存率的提高相关；但由于目前尚无有效的全身治疗方法，患者仍有远处转移失败的风险。因此，关于其适当的治疗方法仍存在争议，本文的综述旨在为此提供帮助。
